A Single Center, Randomized, Double-blind, Placebo-controlled, Parallel Group Design Study to Investigate the Effect of 12,5 mg, 25 mg, 50 mg and 75 mg Neramexane Mesylate IR Tablet on Driving Fitness and Capability to Operate Machines in Healthy Voluntee.
Phase of Trial: Phase I
Latest Information Update: 09 Dec 2009
At a glance
- Drugs Neramexane (Primary)
- Indications Pathologic nystagmus; Tinnitus
- Focus Pharmacodynamics
- 17 Apr 2009 New trial record